Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Subscribe To Our Newsletter & Stay Updated
